Mo Afarideh, MD MPH

PGY-3 Dermatology Resident🧴@MayoClinic | TY @StElizabethsMC | Former Research Fellow @werthlab @MayoClinic | Interested in all things skin. #DermTwitter

[Mo Afarideh, MD MPH @MoAfarideh]

I AM GOING TO BE A DERMATOLOGIST!!!🥳🎉
It feels unreal to match derm at my dream program!!!
Extremely grateful for my mentors, family and friends who supported me every step of the way and continued to push me forward.
#dermtwitter #MedTwitter #Match2023 #dermatology #dermmatch

[Mo Afarideh, MD MPH @MoAfarideh]

How common various skin conditions are in pediatric inflammatory bowel disease, and is there any correlation with disease severity? Hot off the press, check out our single-center experience over 18 years from @MayoClinic Dermatology.
@PeDRAResearch

https://t.co/3hWzAi3cG1

[Mo Afarideh, MD MPH @MoAfarideh]

@DrKShahwan Congratulations!!

[Mo Afarideh, MD MPH @MoAfarideh]

@rashchoices Thank you! Very excited!!

[Mo Afarideh, MD MPH @MoAfarideh]

I AM GOING TO BE A DERMATOLOGIST!!!🥳🎉
It feels unreal to match derm at my dream program!!!
Extremely grateful for my mentors, family and friends who supported me every step of the way and continued to push me forward.
#dermtwitter #MedTwitter #Match2023 #dermatology #dermmatch

[Mo Afarideh, MD MPH @MoAfarideh]

@smsaadatagah ❤️

[Mo Afarideh, MD MPH @MoAfarideh]

@jack_newcomer Congrats Jack!! Can’t wait to start residency and work together!

[Mo Afarideh, MD MPH @MoAfarideh]

@AtaSalabati Following in the footsteps of the bests!❤️

[Mo Afarideh, MD MPH @MoAfarideh]

@ZachHopkinsMD Congratulations!

[Mo Afarideh, MD MPH @MoAfarideh]

Latest review from our group @werthlab on the presentation and approach to the management of bullous systemic lupus erythematosus in females.
https://t.co/r4fxwvZhUG

[Werth Lab @werthlab]

Latest from Grant Sprow and others from our group in @FrontImmunol! Autoimmune Skin Disease Exacerbations Following COVID-19 #Vaccination. Flares were higher in #dermatomyositis but overall #vaccines still outweigh risks for most pts https://t.co/ttubAXOf7W

[Werth Lab @werthlab]

Latest from our group on #pemphigoid by @MoAfarideh Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets https://t.co/Exn1HkHOFV #mdpijcm via @JCM_MDPI

[Werth Lab @werthlab]

Our latest study, Preliminary Definition of Cutaneous Flare in #Dermatomyositis, is available online in @JAADjournals by @joshd102 et al! #dermtwitter #RheumTwitter
https://t.co/ECk4oMuQhj

[Mo Afarideh, MD MPH @MoAfarideh]

@smsaadatagah @bcmhouston @iftikhar_kullo @MayoClinic_KLab @BCM_InternalMed @BCM_CVRI So well deserved buddy!🤩🎉🎉

[Mo Afarideh, MD MPH @MoAfarideh]

@AtaSalabati @RaziyehMahmoud1 @VCU @MidAtl_Retina @Wills_Eye So well deserved! Fantastic news & big congrats to you both 🎉🎊 @RaziyehMahmoud1

[Mo Afarideh, MD MPH @MoAfarideh]

Link to the Cochrane Review:
https://t.co/LKdX7DVcOA

[Mo Afarideh, MD MPH @MoAfarideh]

See our Clinical Evidence Synopsis @JAMADerm summarizing a recent Cochrane Review on the interventions for cutaneous disease in SLE. Take Home Message: higher-quality RCTs using more objective skin-specific outcome measures needed.
@werthlab
https://t.co/YNvyhPFZDJ

[BJD @BrJDermatol]

➡️High doses of oral steroids (prednisone/prednisolone, 1 mg/kg/day) are effective but poorly tolerated in patients with bullous pemphigoid (BP)

➡️Oral prednisone at 0.5 mg/kg/day is an effective and safe alternative in patients with mild or moderate BP

https://t.co/mzZehPRCLT

[Mo Afarideh, MD MPH @MoAfarideh]

Link to the original research:
https://t.co/BMy34daIhE

[Mo Afarideh, MD MPH @MoAfarideh]

Check our commentary @BrJDermatol on a validated trichloroacetic acid (TCA)-based in vivo model to reproduce acne-induced post-inflammatory hyperpigmentation/erythema, with TCA 30%-induced lesions identical to those of the natural acne-induced ➡️

[Mo Afarideh, MD MPH @MoAfarideh]

⬅️ On a molecular level, increased miRNA‐31 and decreased miRNA‐23b may play a pathogenic role in this aberrant pigmentary response. 
@werthlab

Link to the commentary: https://t.co/HpBCgVwHuL